首页> 美国卫生研究院文献>Orphanet Journal of Rare Diseases >Idiopathic non-cirrhotic portal hypertension: a review
【2h】

Idiopathic non-cirrhotic portal hypertension: a review

机译:特发性非肝硬化性门静脉高压症

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Idiopathic non-cirrhotic portal hypertension (INCPH) is a rare disease characterized of intrahepatic portal hypertension in the absence of cirrhosis or other causes of liver disease and splanchnic venous thrombosis. The etiology of INCPH can be classified in five categories: 1) immunological disorders (i.e. association with common variable immunodeficiency syndrome, connective tissue diseases, Crohn’s disease, etc.), 2) chronic infections, 3) exposure to medications or toxins (e.g. azathioprine, 6- thioguanine, arsenic), 4) genetic predisposition (i.e. familial aggregation and association with Adams-Oliver syndrome and Turner disease) and 5) prothrombotic conditions (e.g. inherited thrombophilias myeloproliferative neoplasm antiphospholipid syndrome). Roughly, INCPH diagnosis is based on clinical criteria and the formal exclusion of any other causes of portal hypertension. A formal diagnosis is based on the following criteria: 1) presence of unequivocal signs of portal hypertension, 2) absence of cirrhosis, advanced fibrosis or other causes of chronic liver diseases, and 3) absence of thrombosis of the hepatic veins or of the portal vein at imaging. Patients with INCPH usually present with signs or symptoms of portal hypertension such as gastro-esophageal varices, variceal bleeding or splenomegaly. Ascites and/or liver failure can occur in the context of precipitating factors. The development of portal vein thrombosis is common. Survival is manly limited by concomitant disorders. Currently, treatment of INCPH relies on the prevention of complications related to portal hypertension, following current guidelines of cirrhotic portal hypertension. No treatment has been studied aimed to modify the natural history of the disease. Anticoagulation therapy can be considered in patients who develop portal vein thrombosis.
机译:特发性非肝硬化性门静脉高压症(INCPH)是一种罕见疾病,其特征是在没有肝硬化或其他肝病和内脏静脉血栓形成的情况下发生肝内门静脉高压症。 INCPH的病因可分为五类:1)免疫系统疾病(即与常见的可变免疫缺陷综合症,结缔组织疾病,克罗恩病等相关),2)慢性感染,3)接触药物或毒素(例如硫唑嘌呤) ,6-硫鸟嘌呤,砷),4)遗传易感性(即家族聚集和与Adams-Oliver综合征和特纳病的关联)和5)血栓形成性疾病(例如遗传性血友病,骨髓增生性肿瘤抗磷脂综合征)。粗略地,INCPH诊断是基于临床标准和对门静脉高压症的任何其他原因的正式排除。正式诊断基于以下标准:1)存在明确的门脉高压征兆,2)不存在肝硬化,晚期纤维化或其他引起慢性肝病的原因,以及3)不存在肝静脉或门脉血栓形成成像时静脉。 INCPH患者通常表现为门静脉高压症的体征或症状,例如胃食管静脉曲张,静脉曲张破裂出血或脾肿大。腹水和/或肝功能衰竭可能发生在诱发因素的背景下。门静脉血栓形成的发展是常见的。生存受到伴随疾病的严重限制。当前,INCPH的治疗依赖于根据当前肝硬化性门静脉高压症的指南来预防与门静脉高压症有关的并发症。尚未研究旨在改变疾病自然史的治疗方法。发生门静脉血栓形成的患者可以考虑抗凝治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号